image
Healthcare - Medical - Devices - NASDAQ - US
$ 51.3
-5.85 %
$ 7.78 B
Market Cap
24.78
P/E
1. INTRINSIC VALUE

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits.[ Read More ]

The intrinsic value of one BRKR stock under the base case scenario is HIDDEN Compared to the current market price of 51.3 USD, Bruker Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BRKR

image
FINANCIALS
2.96 B REVENUE
17.14%
437 M OPERATING INCOME
0.97%
427 M NET INCOME
43.12%
350 M OPERATING CASH FLOW
33.63%
-326 M INVESTING CASH FLOW
-36.23%
-193 M FINANCING CASH FLOW
53.42%
864 M REVENUE
7.96%
68.1 M OPERATING INCOME
-8.10%
41.4 M NET INCOME
444.74%
38.4 M OPERATING CASH FLOW
3390.91%
-66.6 M INVESTING CASH FLOW
94.97%
-2.7 M FINANCING CASH FLOW
-0.23%
Balance Sheet Decomposition Bruker Corporation
image
Current Assets 2.16 B
Cash & Short-Term Investments 488 M
Receivables 622 M
Other Current Assets 1.05 B
Non-Current Assets 2.09 B
Long-Term Investments 8.3 M
PP&E 691 M
Other Non-Current Assets 1.39 B
Current Liabilities 1.2 B
Accounts Payable 203 M
Short-Term Debt 144 M
Other Current Liabilities 855 M
Non-Current Liabilities 1.63 B
Long-Term Debt 1.22 B
Other Non-Current Liabilities 415 M
EFFICIENCY
Earnings Waterfall Bruker Corporation
image
Revenue 2.96 B
Cost Of Revenue 1.45 B
Gross Profit 1.52 B
Operating Expenses 1.08 B
Operating Income 437 M
Other Expenses 9.7 M
Net Income 427 M
RATIOS
51.17% GROSS MARGIN
51.17%
14.74% OPERATING MARGIN
14.74%
14.41% NET MARGIN
14.41%
31.02% ROE
31.02%
10.05% ROA
10.05%
12.96% ROIC
12.96%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bruker Corporation
image
Net Income 427 M
Depreciation & Amortization 115 M
Capital Expenditures -107 M
Stock-Based Compensation 24 M
Change in Working Capital -87.8 M
Others -88.8 M
Free Cash Flow 243 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bruker Corporation
image
Wall Street analysts predict an average 1-year price target for BRKR of $78.3 , with forecasts ranging from a low of $77 to a high of $80 .
BRKR Lowest Price Target Wall Street Target
77 USD 50.10%
BRKR Average Price Target Wall Street Target
78.3 USD 52.70%
BRKR Highest Price Target Wall Street Target
80 USD 55.95%
4. DIVIDEND ANALYSIS
0.07% DIVIDEND YIELD
0.05 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Bruker Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
296 K USD 1
6-9 MONTHS
5.03 M USD 3
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
3 months ago
Aug 15, 2024
Sell 296 K USD
ROSENTHAL BOB
Director
- 4684
63.14 USD
8 months ago
Mar 04, 2024
Sell 1.24 M USD
Requardt Hermann Fritz
Director
- 13772
90.1 USD
8 months ago
Mar 04, 2024
Sell 110 K USD
Requardt Hermann Fritz
Director
- 1228
89.61 USD
8 months ago
Feb 28, 2024
Sell 1.19 M USD
Busse Falko
PRESIDENT, BIOSPIN GROUP
- 13852
86.06 USD
8 months ago
Feb 28, 2024
Sell 1.09 M USD
Busse Falko
PRESIDENT, BIOSPIN GROUP
- 12770
84.97 USD
8 months ago
Feb 28, 2024
Sell 127 K USD
Busse Falko
PRESIDENT, BIOSPIN GROUP
- 1500
84.48 USD
8 months ago
Feb 22, 2024
Sell 1.28 M USD
Prause Burkhard
PRES. & CEO, BRUKER BEST
- 15319
83.3 USD
1 year ago
Aug 08, 2023
Sell 2.46 M USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 37947
64.81 USD
1 year ago
Jun 16, 2023
Sell 1.07 M USD
Herman Gerald N
EXECUTIVE VICE PRESIDENT, CFO
- 14242
75.42 USD
1 year ago
May 19, 2023
Sell 838 K USD
Kastner Marc A
Director
- 11146
75.22 USD
1 year ago
May 15, 2023
Sell 10 M USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 137718
72.6 USD
1 year ago
May 15, 2023
Sell 3.49 M USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 47657
73.18 USD
1 year ago
May 16, 2023
Sell 943 K USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 12917
73.03 USD
1 year ago
May 16, 2023
Sell 126 K USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 1708
73.68 USD
1 year ago
May 08, 2023
Sell 6.29 M USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 81745
76.99 USD
1 year ago
May 08, 2023
Sell 531 K USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 6832
77.71 USD
1 year ago
May 08, 2023
Sell 34.6 K USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 441
78.53 USD
1 year ago
May 09, 2023
Sell 2.26 M USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 30359
74.44 USD
1 year ago
May 09, 2023
Sell 5.32 M USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 70598
75.39 USD
1 year ago
May 09, 2023
Sell 763 K USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 10025
76.12 USD
1 year ago
May 03, 2023
Sell 1.3 M USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 16435
79.21 USD
1 year ago
May 01, 2023
Sell 5.89 M USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 74894
78.68 USD
1 year ago
May 01, 2023
Sell 627 K USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 7901
79.38 USD
1 year ago
May 02, 2023
Sell 3.99 M USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 51294
77.7 USD
1 year ago
May 02, 2023
Sell 3.87 M USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 49476
78.27 USD
1 year ago
Apr 24, 2023
Sell 11.8 M USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 146122
81.01 USD
1 year ago
Apr 24, 2023
Sell 172 K USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 2108
81.65 USD
1 year ago
Apr 25, 2023
Sell 1.07 M USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 13793
77.87 USD
1 year ago
Apr 25, 2023
Sell 2.4 M USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 30343
79.06 USD
1 year ago
Apr 25, 2023
Sell 573 K USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 7174
79.82 USD
1 year ago
Apr 25, 2023
Sell 37.1 K USD
LAUKIEN FRANK H
PRESIDENT & CEO
- 460
80.64 USD
1 year ago
Jan 17, 2023
Sell 62.9 K USD
Friend Cynthia M
Director
- 921
68.26 USD
1 year ago
Dec 06, 2022
Sell 1.32 M USD
PACKER RICHARD A
Director
- 20000
66.183 USD
2 years ago
Nov 15, 2022
Sell 707 K USD
Kastner Marc A
Director
- 10000
70.749 USD
2 years ago
May 11, 2022
Bought 98.6 K USD
LAUKIEN FRANK H
PRESIDENT & CEO
+ 1710
57.637 USD
2 years ago
May 11, 2022
Bought 98.6 K USD
LAUKIEN FRANK H
director: PRESIDENT & CEO
+ 1710
57.637 USD
2 years ago
Feb 18, 2022
Sell 1.84 M USD
LAUKIEN FRANK H
CEO, President
- 26790
68.5068 USD
2 years ago
Feb 17, 2022
Sell 1.78 M USD
LAUKIEN FRANK H
CEO, President
- 26200
68.12 USD
2 years ago
Dec 15, 2021
Sell 1.69 M USD
Munch Mark
Exec VP&Pres Bruker Nano Inc.
- 21210
79.4742 USD
2 years ago
Nov 24, 2021
Sell 769 K USD
Kastner Marc A
Director
- 10000
76.86 USD
3 years ago
Sep 02, 2021
Sell 18.1 M USD
Srega Juergen
Group President Bruker CALID
- 202216
89.5397 USD
3 years ago
Aug 16, 2021
Sell 6 M USD
LAUKIEN FRANK H
CEO, President
- 71594
83.8307 USD
3 years ago
Aug 16, 2021
Sell 874 K USD
Prause Burkhard
Pres. & CEO, Bruker EST
- 10446
83.6564 USD
3 years ago
Mar 22, 2021
Sell 109 K USD
Friend Cynthia M
Director
- 1800
60.4253 USD
3 years ago
Jan 07, 2021
Sell 69.9 K USD
Kastner Marc A
Director
- 1236
56.56 USD
3 years ago
Dec 21, 2020
Sell 97.8 K USD
Friend Cynthia M
Director
- 1800
54.32 USD
3 years ago
Dec 15, 2020
Sell 191 K USD
Friend Cynthia M
Director
- 3473
54.95 USD
4 years ago
Nov 10, 2020
Sell 240 K USD
Prause Burkhard
Pres. & CEO, Bruker EST
- 5000
47.93 USD
4 years ago
Sep 21, 2020
Sell 30.1 K USD
Friend Cynthia M
Director
- 800
37.5813 USD
4 years ago
Jun 22, 2020
Sell 73 K USD
Friend Cynthia M
Director
- 1800
40.57 USD
4 years ago
May 11, 2020
Sell 39.1 K USD
Friend Cynthia M
Director
- 1000
39.064 USD
4 years ago
May 11, 2020
Sell 1.16 M USD
Martin Gilles Gerard Jean
Director
- 30000
38.8317 USD
4 years ago
May 11, 2020
Bought 97.8 K USD
LAUKIEN FRANK H
CEO, President
+ 2500
39.11 USD
4 years ago
Dec 16, 2019
Sell 885 K USD
PACKER RICHARD A
Director
- 18000
49.1777 USD
5 years ago
Nov 07, 2019
Sell 152 K USD
Kastner Marc A
Director
- 3203
47.3855 USD
5 years ago
Sep 16, 2019
Sell 2.02 M USD
Munch Mark
Exec VP&Pres Bruker Nano Inc.
- 47203
42.8652 USD
5 years ago
Sep 05, 2019
Sell 675 K USD
Prause Burkhard
Pres. & CEO, Bruker EST
- 15702
42.96 USD
5 years ago
Jun 03, 2019
Sell 16.6 M USD
LAUKIEN FRANK H
CEO, President
- 400000
41.478 USD
5 years ago
May 29, 2019
Sell 13 M USD
LAUKIEN FRANK H
CEO, President
- 313705
41.4741 USD
5 years ago
May 29, 2019
Sell 84.6 K USD
LAUKIEN FRANK H
CEO, President
- 2000
42.3068 USD
5 years ago
May 30, 2019
Sell 3.5 M USD
LAUKIEN FRANK H
CEO, President
- 84295
41.4769 USD
5 years ago
May 15, 2019
Sell 57.4 K USD
Kastner Marc A
Director
- 1374
41.7853 USD
7 years ago
Sep 13, 2017
Sell 631 K USD
Munch Mark
Exec VP&Pres Bruker Nano Inc.
- 21061
29.9699 USD
7 years ago
Aug 10, 2017
Bought 64 K USD
LAUKIEN FRANK H
CEO, President
+ 2335
27.3935 USD
7 years ago
Jun 14, 2017
Sell 558 K USD
VAN INGEN CHRIS
Director
- 19900
28.0346 USD
7 years ago
Jun 13, 2017
Sell 677 K USD
KNISS RICHARD
Director
- 24000
28.2266 USD
7 years ago
Jun 08, 2017
Sell 2.04 M USD
Munch Mark
Exec VP&Pres Bruker Nano Inc.
- 73724
27.6233 USD
7 years ago
May 19, 2017
Bought 83.6 K USD
LAUKIEN FRANK H
CEO, President
+ 3200
26.1348 USD
7 years ago
May 18, 2017
Bought 921 K USD
LAUKIEN FRANK H
CEO, President
+ 35000
26.325 USD
7 years ago
May 17, 2017
Bought 992 K USD
LAUKIEN FRANK H
CEO, President
+ 38000
26.1141 USD
7 years ago
May 16, 2017
Bought 49.7 K USD
LAUKIEN FRANK H
CEO, President
+ 1920
25.8785 USD
7 years ago
Mar 17, 2017
Bought 100 K USD
LAUKIEN FRANK H
CEO, President
+ 4300
23.3407 USD
7 years ago
Mar 13, 2017
Bought 54.6 K USD
LAUKIEN FRANK H
CEO, President
+ 2300
23.7363 USD
7 years ago
Feb 24, 2017
Sell 84.7 K USD
Lenggenhager Rene
President, BioSpin Group
- 3539
23.9269 USD
7 years ago
Dec 15, 2016
Bought 100 K USD
LAUKIEN FRANK H
CEO, President
+ 4725
21.2194 USD
7 years ago
Dec 13, 2016
Sell 446 K USD
VAN INGEN CHRIS
Director
- 20000
22.2918 USD
7 years ago
Nov 25, 2016
Bought 48.6 K USD
LAUKIEN FRANK H
CEO, President
+ 2124
22.8961 USD
8 years ago
Aug 10, 2016
Bought 8.79 K USD
PACKER RICHARD A
Director
+ 400
21.9642 USD
8 years ago
Aug 10, 2016
Bought 134 K USD
PACKER RICHARD A
Director
+ 6100
21.97 USD
8 years ago
Aug 10, 2016
Bought 76.9 K USD
PACKER RICHARD A
Director
+ 3500
21.9685 USD
8 years ago
Aug 05, 2016
Bought 99.8 K USD
LAUKIEN FRANK H
CEO, President
+ 4500
22.167 USD
8 years ago
Jun 14, 2016
Bought 100 K USD
LAUKIEN FRANK H
CEO, President
+ 4174
23.9479 USD
8 years ago
Jun 06, 2016
Sell 51.3 M USD
LAUKIEN JOERG C
director, 10 percent owner:
- 2000000
25.65 USD
8 years ago
May 09, 2016
Sell 620 K USD
FURLONG BRENDA J
Director
- 22600
27.4353 USD
8 years ago
May 09, 2016
Sell 574 K USD
Emmerich Wolf-Dieter
Director
- 21000
27.3507 USD
8 years ago
Mar 10, 2016
Sell 2.08 M USD
Munch Mark
Exec VP&Pres Bruker Nano Inc.
- 75000
27.6958 USD
9 years ago
Jun 15, 2015
Bought 19.5 M USD
LAUKIEN FRANK H
CEO, President
+ 1000000
19.5 USD
9 years ago
Jun 15, 2015
Sell 19.5 M USD
LAUKIEN JOERG C
director, 10 percent owner:
- 1000000
19.5 USD
9 years ago
Jun 11, 2015
Sell 307 K USD
Fesik Stephen W.
Director
- 15000
20.484 USD
9 years ago
Jun 09, 2015
Bought 100 K USD
LAUKIEN FRANK H
CEO/President
+ 4930
20.2813 USD
9 years ago
Jun 11, 2015
Bought 9.88 K USD
LAUKIEN FRANK H
CEO/President
+ 480
20.576 USD
9 years ago
Jun 10, 2015
Bought 10 K USD
LAUKIEN FRANK H
CEO/President
+ 491
20.3855 USD
9 years ago
Mar 17, 2015
Sell 360 K USD
WAGNER CHARLES F JR
EVP & Chief Financial Officer
- 19000
18.9733 USD
9 years ago
Mar 05, 2015
Bought 225 K USD
PACKER RICHARD A
Director
+ 11856
19 USD
9 years ago
Mar 05, 2015
Bought 35.4 K USD
PACKER RICHARD A
Director
+ 1864
18.98 USD
9 years ago
Mar 05, 2015
Bought 24.3 K USD
PACKER RICHARD A
Director
+ 1280
18.99 USD
9 years ago
Feb 25, 2015
Bought 52.1 K USD
LAUKIEN FRANK H
CEO, President
+ 2771
18.7895 USD
9 years ago
Feb 24, 2015
Bought 47.8 K USD
LAUKIEN FRANK H
CEO, President
+ 2500
19.1321 USD
7. News
New Strong Sell Stocks for November 12th BRKR, CMC and CNXC have been added to the Zacks Rank #5 (Strong Sell) List on November 12, 2024. zacks.com - 4 days ago
Bruker Corporation to Present at Upcoming Investor Conferences BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: Stifel 2024 Healthcare Conference in New York City Monday, November 18, 2024, at 8:35 a.m. Eastern Time Wolfe Research 2024 Healthcare Conference in New York City Tuesday, November 19, 2024, at 4:10 p.m. Eastern Time Nasdaq 51st Investor Conference in London, UK Tuesday, December 1. businesswire.com - 4 days ago
BRKR Stock Declines Despite Launching EpicIF Technology for CellScape Bruker's new technology, EpicIF, is set to enhance the CellScape Precise Spatial Proteomics platform. zacks.com - 5 days ago
Bruker Announces EpicIFTM, Revolutionary Fluorescence Signal Removal Technology, Transforming CellScape Spatial Proteomics Platform BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a major technological breakthrough in the CellScape™ Precise Spatial Proteomics platform for highly multiplexed immunofluorescence (IF). Launched in 2022, the CellScape platform has advanced the field of spatial proteomics with differentiated quantitative performance enabled by a unique combination of best-in-class resolution and high dynamic range (HDR) imaging. CellScape captures the entire continuum of prote. businesswire.com - 1 week ago
BRKR Misses on Q3 Earnings, Cuts '24 View, Stock Up in Aftermarket Bruker delivers robust revenue growth in the third quarter despite soft general market conditions. zacks.com - 1 week ago
Bruker Corporation (BRKR) Q3 2024 Earnings Call Transcript Bruker Corporation (NASDAQ:BRKR ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Joe Kostka - Director, Investor Relations Frank Laukien - President and CEO Gerald Herman - Executive Vice President and CFO Conference Call Participants Puneet Souda - Leerink Partners Michael Ryskin - Bank of America Patrick Donnelly - Citi Rachel Vatnsdal - JPMorgan Tycho Peterson - Jefferies Josh Waldman - Cleveland Research Dan Brennan - TD Cowen Brandon Couillard - Wells Fargo Luke Sergott - Barclays Operator Good day. And welcome to the Bruker Corporation Third Quarter 2024 Earnings Call. seekingalpha.com - 1 week ago
Bruker (BRKR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Bruker (BRKR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 week ago
Bruker (BRKR) Q3 Earnings and Revenues Lag Estimates Bruker (BRKR) came out with quarterly earnings of $0.60 per share, missing the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.74 per share a year ago. zacks.com - 1 week ago
Bruker Reports Third Quarter 2024 Financial Results BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for its third quarter and for the nine months ended September 30, 2024. Frank H. Laukien, Bruker's President and CEO, commented: “Bruker has again posted double-digit year-over-year CER revenue growth, and above-market organic revenue growth, in Q3 and year-to-date. This is a testament to our Project Accelerate transformation, and to our operational excellence processes driving improvements in. businesswire.com - 1 week ago
Analysts Estimate Bruker (BRKR) to Report a Decline in Earnings: What to Look Out for Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 weeks ago
Bruker Announces Date and Time of Third Quarter 2024 Earnings Release and Webcast BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2024 financial results before market opening on Tuesday, November 5, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q3 2024 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide prese. businesswire.com - 2 weeks ago
Bruker Announces One-Hundred Dollar, Deep, High-Accuracy Plasma Proteome; Advances Glycoproteomics and Metaproteomics DRESDEN, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--At the 23rd Human Proteome Organization World Congress, Bruker Corporation (Nasdaq: BRKR) announces advances in deep, unbiased and high-sensitivity 4D-Proteomics for robust, high- fidelity, large-scale studies - avoiding inherent cross-talk of affinity high-plex technologies. A. Enhanced specificity and proteome coverage using diagonal-PASEF Leveraging scanning quadrupole and trapped ion mobility spectrometry (TIMS), diagonal-PASEF was introduced in 2023 by ke. businesswire.com - 3 weeks ago
8. Profile Summary

Bruker Corporation BRKR

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 7.78 B
Dividend Yield 0.07%
Description Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Contact 40 Manning Road, Billerica, MA, 01821 https://www.bruker.com
IPO Date Aug. 4, 2000
Employees 9707
Officers Dr. Falko Busse Ph.D. President of Bruker BioSpin Group Mr. Juergen Srega President of Bruker CALID Group & Bruker Daltonics Division Mr. J. Brent Alldredge J.D. General Counsel & Secretary Dr. Mark R. Munch Ph.D. Corporate Executive Vice President and President of Bruker Nano Group & Corporate Dr. Frank H. Laukien Ph.D. Chairman, Chief Executive Officer & President Mr. Justin Joseph Ward Senior Director of Investor Relations & Corporate Development Dr. Burkhard Prause Ph.D. President and Chief Executive Officer of Bruker Energy & Supercon Technologies, Inc.